Literature DB >> 15626900

Interleukin 10-deficient mice exhibit defective colonic Muc2 synthesis before and after induction of colitis by commensal bacteria.

Nicole M J Schwerbrock1, Mireille K Makkink, Maria van der Sluis, Hans A Büller, Alexandra W C Einerhand, R Balfour Sartor, Jan Dekker.   

Abstract

Germ-free (GF) interleukin 10-deficient (IL-10) mice develop chronic colitis after colonization by normal enteric bacteria. Muc2 is the major structural component of the protective colonic mucus. Our aim was to determine whether primary or induced aberrations in Muc2 synthesis occur in GF IL-10 mice that develop colitis after bacterial colonization. GF IL-10 and wild-type mice were colonized with commensal bacteria for various intervals up to 6 weeks. Colitis was quantified by histologic score and IL-12 secretion. Muc2 synthesis, total level of Muc2, and Muc2 sulfation were measured quantitatively. GF IL-10 mice showed 10-fold lower Muc2 synthesis and Muc2 levels compared with GF wild-type mice, but Muc2 sulfation was not different. When bacteria were introduced, IL-10 mice developed colitis, whereas wild-type mice remained healthy. Muc2 synthesis was unchanged in wild-type mice, but IL-10 mice showed a peak increase in Muc2 synthesis 1 week after bacterial introduction, returning to baseline levels after 2 weeks. Total Muc2 levels decreased 2-fold in wild-type mice but remained at stable low levels in IL-10 mice. Upon introducing bacteria, Muc2 sulfation increased 2-fold in wild-type mice, whereas in IL-10 mice Muc2 sulfation decreased 10-fold. In conclusion, a primary defect in colonic Muc2 synthesis is present in IL-10 mice, whereas bacterial colonization and colitis in these mice led to reduced Muc2 sulfation. These quantitative and structural aberrations in Muc2 in IL-10 mice likely reduce the ability of their mucosa to cope with nonpathogenic commensal bacteria and may contribute to their susceptibility to develop colitis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15626900     DOI: 10.1097/00054725-200411000-00016

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  22 in total

Review 1.  T-cell activation in the intestinal mucosa.

Authors:  Dina Montufar-Solis; Tomas Garza; John R Klein
Journal:  Immunol Rev       Date:  2007-02       Impact factor: 12.988

2.  Ectopic expression of blood type antigens in inflamed mucosa with higher incidence of FUT2 secretor status in colonic Crohn's disease.

Authors:  Jun Miyoshi; Tomoharu Yajima; Susumu Okamoto; Katsuyoshi Matsuoka; Nagamu Inoue; Tadakazu Hisamatsu; Katsuyoshi Shimamura; Atsushi Nakazawa; Takanori Kanai; Haruhiko Ogata; Yasushi Iwao; Makio Mukai; Toshifumi Hibi
Journal:  J Gastroenterol       Date:  2011-07-05       Impact factor: 7.527

Review 3.  Genetically engineered mucin mouse models for inflammation and cancer.

Authors:  Suhasini Joshi; Sushil Kumar; Sangeeta Bafna; Satyanarayana Rachagani; Kay-Uwe Wagner; Maneesh Jain; Surinder K Batra
Journal:  Cancer Metastasis Rev       Date:  2015-12       Impact factor: 9.264

Review 4.  The gut microbiota, bacterial metabolites and colorectal cancer.

Authors:  Petra Louis; Georgina L Hold; Harry J Flint
Journal:  Nat Rev Microbiol       Date:  2014-09-08       Impact factor: 60.633

Review 5.  Emerging potential of natural products for targeting mucins for therapy against inflammation and cancer.

Authors:  Muzafar A Macha; Shiv Ram Krishn; Rahat Jahan; Kasturi Banerjee; Surinder K Batra; Maneesh Jain
Journal:  Cancer Treat Rev       Date:  2015-01-14       Impact factor: 12.111

6.  Time for a gut check: evidence for the hypothesis that HLA-B27 predisposes to ankylosing spondylitis by altering the microbiome.

Authors:  James T Rosenbaum; Michael P Davey
Journal:  Arthritis Rheum       Date:  2011-11

7.  Intestinal inflammation targets cancer-inducing activity of the microbiota.

Authors:  Janelle C Arthur; Ernesto Perez-Chanona; Marcus Mühlbauer; Sarah Tomkovich; Joshua M Uronis; Ting-Jia Fan; Barry J Campbell; Turki Abujamel; Belgin Dogan; Arlin B Rogers; Jonathan M Rhodes; Alain Stintzi; Kenneth W Simpson; Jonathan J Hansen; Temitope O Keku; Anthony A Fodor; Christian Jobin
Journal:  Science       Date:  2012-08-16       Impact factor: 47.728

Review 8.  Mucins in cancer: function, prognosis and therapy.

Authors:  Donald W Kufe
Journal:  Nat Rev Cancer       Date:  2009-12       Impact factor: 60.716

Review 9.  Mucin-Microbiota Interaction During Postnatal Maturation of the Intestinal Ecosystem: Clinical Implications.

Authors:  Sana Rokhsefat; Aifeng Lin; Elena M Comelli
Journal:  Dig Dis Sci       Date:  2016-01-20       Impact factor: 3.199

Review 10.  Unraveling mucin domains in cancer and metastasis: when protectors become predators.

Authors:  Koelina Ganguly; Sanchita Rauth; Saravanakumar Marimuthu; Sushil Kumar; Surinder K Batra
Journal:  Cancer Metastasis Rev       Date:  2020-09       Impact factor: 9.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.